Regnum Corp Stock Performance
| RGMP Stock | USD 0.0001 0.00 0.00% |
The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and Regnum Corp are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Regnum Corp has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable primary indicators, Regnum Corp is not utilizing all of its potentials. The latest stock price agitation, may contribute to short-term losses for the retail investors. ...more
Regnum |
Regnum Corp Relative Risk vs. Return Landscape
If you would invest 0.01 in Regnum Corp on September 26, 2025 and sell it today you would earn a total of 0.00 from holding Regnum Corp or generate 0.0% return on investment over 90 days. Regnum Corp is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Regnum, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Regnum Corp Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Regnum Corp's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Regnum Corp, and traders can use it to determine the average amount a Regnum Corp's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| RGMP |
Based on monthly moving average Regnum Corp is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Regnum Corp by adding Regnum Corp to a well-diversified portfolio.
Regnum Corp Fundamentals Growth
Regnum Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Regnum Corp, and Regnum Corp fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Regnum Pink Sheet performance.
| Return On Asset | -1.03 | |||
| Current Valuation | 4.25 M | |||
| Shares Outstanding | 22.95 M | |||
| Price To Book | 7,858 X | |||
| Price To Sales | 3,337 X | |||
| Revenue | 9 K | |||
| EBITDA | (112.86 K) | |||
| Cash And Equivalents | 1.26 M | |||
| Cash Per Share | 0.05 X | |||
| Total Debt | 1.53 M | |||
| Book Value Per Share | (0.04) X | |||
| Cash Flow From Operations | (3.67 K) | |||
| Earnings Per Share | (0.02) X | |||
| Total Asset | 4.5 K | |||
About Regnum Corp Performance
Assessing Regnum Corp's fundamental ratios provides investors with valuable insights into Regnum Corp's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Regnum Corp is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab , a monoclonal antibody CC chemokine receptor type 5 antagonist, that is designed to prevent human immunodeficiency virus from entering human cells. REGNUM CORP operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1 people.Things to note about Regnum Corp performance evaluation
Checking the ongoing alerts about Regnum Corp for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Regnum Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Regnum Corp generated a negative expected return over the last 90 days | |
| Regnum Corp has some characteristics of a very speculative penny stock | |
| Regnum Corp has a very high chance of going through financial distress in the upcoming years | |
| Regnum Corp currently holds 1.53 M in liabilities. Regnum Corp has a current ratio of 0.61, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Regnum Corp until it has trouble settling it off, either with new capital or with free cash flow. So, Regnum Corp's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Regnum Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Regnum to invest in growth at high rates of return. When we think about Regnum Corp's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 9 K. Net Loss for the year was (117.67 K) with profit before overhead, payroll, taxes, and interest of 6.77 K. | |
| Regnum Corp currently holds about 1.26 M in cash with (3.67 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 99.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Tivic Health Systems Acquires Scorpius Holdings Assets - TipRanks |
- Analyzing Regnum Corp's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Regnum Corp's stock is overvalued or undervalued compared to its peers.
- Examining Regnum Corp's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Regnum Corp's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Regnum Corp's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Regnum Corp's pink sheet. These opinions can provide insight into Regnum Corp's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Regnum Pink Sheet Analysis
When running Regnum Corp's price analysis, check to measure Regnum Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regnum Corp is operating at the current time. Most of Regnum Corp's value examination focuses on studying past and present price action to predict the probability of Regnum Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regnum Corp's price. Additionally, you may evaluate how the addition of Regnum Corp to your portfolios can decrease your overall portfolio volatility.